There is a biological distinction between breast cancers that depend on hormones and those that do not, according to research published in PLoS Genetics* today (Friday).
Scientists previously thought that hormone dependent breast cancers, which usually require treatment with surgery and anti-hormone drugs, originated from the same biological pathway as hormone independent breast cancers, which are treated with surgery and chemotherapy.
The new discovery provides the strongest evidence yet that the subtypes originate from separate pathways and could guide future research into prevention and treatments for the cancer types as different diseases.
Currently, there are fewer treatment options for women with hormone independent breast cancer following surgery.
Cancer Research UK’s Dr Paul Pharoah, lead author based at the University of Cambridge, said: “We looked at five genetic variants associated with breast cancer to see if they were more likely to be found in hormone dependent or independent breast cancers.
“One common genetic variant, FGFR2, was strongly associated with hormone dependent breast cancer, but weakly associated with hormone independent cancer.
“This shows that they have distinct genetic origins, and are different diseases.
“We hope our study will help clarify the biology of breast cancer subtypes and steer future research along two, more distinct paths.”
In the largest study of its kind, the international collaborative effort** funded by Cancer Research UK looked at the genetic makeup of over 23,000 breast cancer cases.
Dr Lesley Walker, Cancer Research UK’s director of cancer information, said: “Scientists were previously unsure how different types of breast cancer developed. Although the findings won’t have any immediate effects on the treatment of women with the disease, they are important in helping to define the next steps in our research on the causes of this major cancer.”
For media enquiries please contact the Cancer Research UK press office on 020 7061 8300 or, out-of-hours, the duty press officer on 07050 264 059.
* Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. Montserrat Garcia-Closas et al. 2008. PLoS Genetics.
** The researchers in this study used data provided by the Breast Cancer Association Consortium (BCAC) – a huge international collaborative group of researchers interested in inherited risk of breast cancer. Co-ordination of BCAC is funded by Cancer Research UK.
Hormone dependent breast cancers are also known as ER positive and hormone independent breast cancers as ER negative.
The University of Cambridge
The University of Cambridge’s reputation for excellence is known worldwide and reflects the scholastic achievements of its academics and students, as well as the world-class original research carried out by its staff. Some of the world’s most significant scientific breakthroughs have occurred at the University, including the splitting of the atom, invention of the jet engine and the discoveries of stem cells, plate tectonics, pulsars and the structure of DNA. From Isaac Newton to Stephen Hawking, the University has nurtured some of history’s greatest minds and has produced more Nobel Prize winners than any other UK institution with over 80 laureates.
About Cancer Research UK
- Together with its partners and supporters, Cancer Research UK’s vision is to beat cancer.
- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
- For further information about Cancer Research UK’s work or to find out how to support the charity, please call 020 7009 8820 or visit our homepage.